作为阿尔茨海默病治疗剂的表观遗传抑制剂
Yasunobu Yamashita1, Yukihiro Itoh1, Yuri Takada1
1SANKEN, Osaka University.
Chemical & pharmaceutical bulletin
|June 30, 2024
概括
针对表观遗传蛋白的新型小分子抑制剂对阿尔茨海默病 (AD) 治疗有希望. 这些药物改善了AD模型小鼠的记忆功能,解决了早期疗法的局限性.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 遗传学 遗传学 是一个
背景情况:
- 阿尔茨海默病 (AD) 是导致痴呆的主要原因,由于人口老龄化,患病率越来越高.
- 目前的阿尔茨海默病治疗方法提供有限的症状缓解,突显了对新型治疗剂的需求.
- 人们越来越认识到表观遗传失调是认知障碍发展的关键因素.
研究的目的:
- 审查针对表观遗传学相关蛋白质的小分子抑制剂,作为阿尔茨海默病的潜在治疗剂.
- 讨论开发口服生物可用,穿透血脑屏障的AD的表观遗传抑制剂的挑战和最近的进展.
- 为了突出显示基因素脱乙酶 (HDAC) 抑制剂,氨酸特异性脱甲酶1 (LSD1) 和体和外终端域 (BET) 蛋白质.
主要方法:
- 对针对表观遗传蛋白质的小分子抑制剂的最新文献的综述.
- 对研究这些抑制剂在阿尔茨海默病模型中的有效性进行分析.
- 专注于具有改善药物动力学特性 (口服,BBB透) 和安全概况的抑制剂.
主要成果:
- 针对HDAC,LSD1和BET蛋白的几种新型小分子抑制剂已经证明了AD治疗的潜力.
- 这些抑制剂在改善阿尔茨海默病模型小鼠的记忆功能方面表现出有效性.
- 最近的药物发现工作正在克服慢性神经退行性疾病早期表观遗传抑制剂的局限性.
结论:
- 像HDAC,LSD1和BET蛋白质这样的表观遗传标的小分子抑制剂代表了阿尔茨海默病的有希望的治疗途径.
- 克服药物输送和选择性方面的挑战对于开发有效的AD治疗至关重要.
- 对这些表观遗传调节器的进一步研究可能会导致AD认知衰退的改善症状药物.
更多相关视频
09:33Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
7.9K
08:01Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
Published on: March 16, 2016
42.3K
相关概念视频
Alzheimer's Disease: Treatment
178
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
178
siRNA - Small Interfering RNAs
16.7K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
16.7K
Alzheimer's Disease: Overview
461
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
461
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
118
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
118
Eukaryotic Transcription Inhibitors
9.8K
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
9.8K
Enzyme Inhibition
78.2K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
78.2K
